TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine . In Vitro TBI-166 inhibits M. tuberculosis H37Rv replicates (MIC: 0.063 μg/mL), and is effective against 16 drug-sensitive clinical isolates (Mycobacterial species) with MICs of 0.005-0.15 μg/mL. TBI-166 (0-1 μg/mL, 3 days) inhibits intracellular M. tuberculosis in M. tuberculosis infecting J774A.1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo TBI-166 (10-80 mg/kg, p.o., 8 weeks) displays antituberculosis activity in chronic murine M. tuberculosis H37Rv infected model . TBI-166 displays a LD50 more than 3,000 mg/kg in mice . TBI-166 has a short half-life (41.25 h) and reduces the potential for skin pigmentation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Chronic murine M. tuberculosis H37Rv infected model Dosage: 10, 20, 80 mg/kg Administration: Oral administration, 8 weeks. Result: Reduced CFU counts in lung. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
TBI-166
CAS number：1353734-12-9 molecular formula：C32H30F3N5O3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1353734-12-9 | molecular formula | C32H30F3N5O3 |
| molecular weight | 589.61 g/mol | Exact mass | ≥98% |
| PSA | 80.600 Ų | logp | 6.600 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
